Hyperphosphataemia: Treatment Options

• Published in: Drugs (New York, N.Y.) Vol. 73; no. 7; pp. 673 - 688
• Main Author: Malberti, Fabio
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing AG 01.05.2013; Adis International; Springer Nature B.V
• Subjects: Biological and medical sciences; Calcification; Chelating Agents - adverse effects; Chelating Agents - therapeutic use; General and cellular metabolism. Vitamins; Hemodialysis; Humans; Hyperphosphatemia - complications; Hyperphosphatemia - diet therapy; Hyperphosphatemia - drug therapy; Hyperphosphatemia - etiology; Hypocalcemia; Internal Medicine; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - diet therapy; Kidney Failure, Chronic - drug therapy; Medical sciences; Medicine; Medicine & Public Health; Mortality; Patients; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pharmacotherapy; Phosphorus; Review Article; Chronic Kidney Disease Patient; Chronic Kidney Disease; Chronic Kidney Disease Stage; Phosphate Binder; Vascular Calcification; Human; Phosphates; Hydroelectrolytic balance disorder; Oral administration; Phosphorus; Review; Inorganic element; Metabolic disorder; Treatment; Lanthanum carbonate; Chelating agent; Hyperphosphatemia; Sevelamer

Hyperphosphataemia can be induced by three main conditions: a massive acute phosphate load, a primary increase in renal phosphate reabsorption, and an impaired renal phosphate excretion due to acute or chronic renal insufficiency. Renal excretion is so efficient in normal subjects that balance can b...